Roche announced that the European Commission has approved Xofluza in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus. The Commission’s Decision is based on the results of the phase III miniSTONE-2 and BLOCKSTONE studies. "This approval marks the first single-dose, oral influenza medicine approved in Europe for children, and now means that Xofluza can be used to treat and prevent uncomplicated influenza in children aged one year and above, and in adolescents and adults," the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- Roche looks internally for pharmaceutical unit chief, Bloomberg reports
- Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab
- Genentech announces FDA acceptance of, grants priority review for glofitamab BLA
- FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma